Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The rapidly spreading, highly contagious and pathogenic SARS-coronavirus 2 (SARS-CoV-2) associated Coronavirus Disease 2019 (COVID-19) has been declared as a pandemic by the World Health Organization (WHO). The novel 2019 SARS-CoV-2 enters the host cell by binding of the viral surface spike glycoprotein (S-protein) to angiotensin converting enzyme 2 (ACE2). The virus specific molecular interaction with the host cell represents a promising therapeutic target for identifying SARS-CoV-2 antiviral drugs. The repurposing of drugs can provide a rapid and potential cure towards exponentially expending COVID-19. Thereto, high-throughput virtual screening approach was used to investigate FDA approved LOPAC library drugs against both the S-protein and ACE2 host cell receptor. Primary screening identified a few promising drugs for both the targets, which were further analyzed in details by their binding energy, binding modes through molecular docking, dynamics and simulations. Evidently, Eptifibatide acetate, TNP, GNF5, GR 127935 hydrochloride hydrate and RS504393 were found binding to virus binding motifs of ACE2 receptor. Additionally, KT185, KT203 GSK1838705A, BMS195614, and RS504393 were identified to bind at the receptor binding site on the viral S-protein. These identified drug molecules may effectively assist in controlling the rapid spread of SARS-COV-2 by not only potentially inhibiting the virus at entry step but also as anti-inflammatory agents which could impart relief in lung injuries. Timely identification and determination of an effective drug to combat and tranquilize the COVID-19 global crisis is the utmost need of hour. Further, prompt in vivo testing to validate the anti-SARS-COV-2 inhibition by these drugs could save lives is justified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 9×
“Computer based high throughput screening was done using PyRx and AutoDock Vina with a grid box centering on Lys31 and Lys353 hotspot residues (Figure 1A).”
BackgroundInfluentialPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581 · cited 1×
“8 (24), Open Babel (25), AutoDock Vina (26), PyMol (27), GROMACS (28) and online resources like SWISS MODEL (29), HADDOCK (30), RCSB PDB (31), NCBI (32), ProCheck at RCSB validation server (33), ProSA-web (34), SAVES-Verify3D server (35), etc.”
BackgroundHoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · cited 1×
“Coronavirus infection in humans is driven mainly by interactions between envelopeanchored spike glycoprotein (S-protein) of CoV and the host cell receptor, angiotensinconverting enzyme 2 (ACE2) (15,16).”
BackgroundWu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
SWISS-MODEL: homology modelling of protein structures and complexes
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,067 · cited 4×
“Homology modeling for S1-subunit of S-protein (residues 319- 529) of SARS-CoV-2 was done using SWISS-MODEL.”
BackgroundInfluentialA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“To this end, structure-based virtual screening approach was used for identifying inhibitor molecules targeting SARS-COV-2 virus-host cell interaction, using the crystal structure of ACE2 complexed with S-RBD and the newly released whole genome sequence of 2019-nCoV (SARS-CoV-2) (23)(24).”
MethodOpen Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,939 · cited 3×
“8 (24), Open Babel (25), AutoDock Vina (26), PyMol (27), GROMACS (28) and online resources like SWISS MODEL (29), HADDOCK (30), RCSB PDB (31), NCBI (32), ProCheck at RCSB validation server (33), ProSA-web (34), SAVES-Verify3D server (35), etc.”
BackgroundInfluentialDatabase resources of the National Center for Biotechnology Information: update
Wheeler, D. L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh073 · Cited by 10,641
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., et al. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt055 · Cited by 7,473 · cited 4×
“For this purpose, GROMACS 5.4.1 suite was used to carry out all simulation studies using GROMOS96 43a1 force field on a LINUX-based workstation.”
BackgroundInfluentialWiederstein, M., & Sippl, M. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm290 · Cited by 5,909
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081 · cited 2×
“Evidently, the key residues of SARS-CoV RBD (Tyr442, Leu472, Asn479, Asp480, and Thr487) are hypothesized to have undergone natural selection in SARS-CoV-2 and have been proposed to play a critical role in cross-species transmission of coronaviruses (19).”
BackgroundResultStructural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 7×
“SARSCOV-2, a member of the Coronaviridae family, is a type of positive-sense, single-stranded enveloped RNA viruses responsible for causing infections in avian, mammalian and marine species across the world (1).”
BackgroundInfluentialSmall-Molecule Library Screening by Docking with PyRx
Dallakyan, S., & Olson, A. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2269-7_19 · Cited by 3,998 · cited 1×
“8 (24), Open Babel (25), AutoDock Vina (26), PyMol (27), GROMACS (28) and online resources like SWISS MODEL (29), HADDOCK (30), RCSB PDB (31), NCBI (32), ProCheck at RCSB validation server (33), ProSA-web (34), SAVES-Verify3D server (35), etc.”
BackgroundStructural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Assessment of protein models with three-dimensional profiles
Lüthy, R., Bowie, J. U., & Eisenberg, D. (1992) · Nature · doi:10.1038/356083a0 · Cited by 3,525
HADDOCK: A Protein−Protein Docking Approach Based on Biochemical or Biophysical Information
Dominguez, C., Boelens, R., & Bonvin, A. M. J. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja026939x · Cited by 3,187 · cited 4×
“The predicted homology model for S1 subunit of S-protein was submitted in PMDB database (PMDB ID: Frontiers in Immunology | www.frontiersin.org 7 July 2020 | Volume 11 | Article 1664 PM0082972), and the HADDOCK tool was used to identify interacting residues between receptor and S-RBD of S-protein (Figure S2).”
BackgroundInfluentialChan, J. F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K. K.-W., Yuan, S., & Yuen, K.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,059 · cited 1×
“~99% similarity whereas the S1 subunit shares 70% similarity with other bat SARS-CoV and human SARS-CoV, but the core RBD domain is highly conserved among them (9,18).”
BackgroundWilder-Smith, A., & Freedman, D. O. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa020 · Cited by 2,727 · cited 2×
“Current prevention and treatment efforts are directed on quarantine and containment of infected patients to prevent human to human transmission (10)(11).”
Background[20] VERIFY3D: Assessment of protein models with three-dimensional profiles
Eisenberg, D., Lüthy, R., & Bowie, J. U. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)77022-8 · Cited by 2,192 · cited 1×
“at RCSB validation server (33), ProSA-web (34), SAVES-Verify3D server (35), etc.”
MethodStructure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031 · cited 1×
“To this end, structure-based virtual screening approach was used for identifying inhibitor molecules targeting SARS-CoV-2 virus-host cell interaction, using the crystal structure of ACE2 complexed with S-RBD and the newly released whole genome sequence of SARS-CoV-2 (22, 23).”
MethodDatabase resources of the National Center for Biotechnology Information
(2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1290 · Cited by 1,470
Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021
Alizon, S., Haim-Boukobza, S., Foulongne, V., Verdurme, L., Trombert-Paolantoni, S., Lecorche, E., Roquebert, B., & Sofonea, M. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.28.2100573 · Cited by 862
Virus entry: molecular mechanisms and biomedical applications
Dimitrov, D. S. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro817 · Cited by 701 · cited 1×
“Viral life cycle involves entry into the host cell after attachment to the host cell receptor, release of genetic material inside cell, synthesis of structural and non-structural proteins and genomic RNA, assembly of mature virus particles followed by budding to exit from host cell (38).”
BackgroundGaunt, E. R., Hardie, A., Claas, E. C. J., Simmonds, P., & Templeton, K. E. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00636-10 · Cited by 699 · cited 1×
“NL63-CoV, HCoV-OC43, and HCoV-HKU1 are a few other coronaviruses responsible for causing infections in humans (9).”
BackgroundWong, S. K., Li, W., Moore, M. J., Choe, H., & Farzan, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300520200 · Cited by 694 · cited 1×
“Coronavirus infection in humans is driven mainly by interactions between envelopeanchored spike glycoprotein (S-protein) of CoV and the host cell receptor, angiotensinconverting enzyme 2 (ACE2) (16)(17).”
BackgroundLiu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., & Liu, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25726 · Cited by 691 · cited 1×
“Infections caused by alpha-coronaviruses (NL63-CoV and HCoV-229E) are usually mild and asymptomatic, whereas beta-coronaviruses like severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), have caused serious epidemics (4).”
BackgroundDhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735227 · Cited by 623 · cited 1×
“Additionally, neutralizing monoclonal antibody-based therapeutics are also being developed to combat COVID-19 crisis (13,14).”
BackgroundSelf-citationTouret, F., & de Lamballerie, X. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104762 · Cited by 541 · cited 6×
“Chimeric S-RBD of SARS-CoV-2 (PDB ID: 6VW1) has been reported, but the structure comprises majorly of SARS-CoV residues and contains only S-RBM of SARS-CoV2.”
BackgroundInfluentialMalik, Y. S., Sircar, S., Bhat, S., Sharun, K., Dhama, K., Dadar, M., Tiwari, R., & Chaicumpa, W. (2020) · Veterinary Quarterly · doi:10.1080/01652176.2020.1727993 · Cited by 498 · cited 3×
“S2 subunit of SARS-CoV-2 is highly conserved with ∼99% similarity whereas the S1 subunit shares 70% similarity with other bat SARS-CoV and human SARS-CoV, but the core RBD domain is highly conserved among them (2, 18).”
BackgroundSelf-citationChemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells
Law, H. K. W., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, J. S. M., & Lau, Y. L. (2005) · Blood · doi:10.1182/blood-2004-10-4166 · Cited by 471
Coronavirus puts drug repurposing on the fast track
Harrison, C. (2020) · Nature Biotechnology · doi:10.1038/d41587-020-00003-1 · Cited by 470 · cited 1×
“Repurposing them for coronavirus infections can be an alternative approach that could help to discover potential antiviral molecules rather quickly (21).”
BackgroundMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)
Jolly, G. (2016) · TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH · doi:10.21522/tijph.2013.04.04.art033 · Cited by 441
Database resources of the National Center for Biotechnology Information
Sayers, E. W., Beck, J., Brister, J. R., Bolton, E. E., Canese, K., Comeau, D. C., Funk, K., Ketter, A., Kim, S., Kimchi, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz899 · Cited by 418
Kindrachuk, J., Ork, B., Hart, B. J., Mazur, S., Holbrook, M. R., Frieman, M. B., Traynor, D., Johnson, R. F., Dyall, J., Kuhn, J. H., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03659-14 · Cited by 407 · cited 2×
“• Responsible for inhibiting MERS-CoV infection by targeting Akt signaling (47, 48).”
BackgroundChakraborty, A., Koldobskiy, M. A., Bello, N. T., Maxwell, M., Potter, J. J., Juluri, K. R., Maag, D., Kim, S., Huang, A. S., Dailey, M. J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.11.032 · Cited by 361 · cited 2×
“• Responsible for inhibiting MERS-CoV infection by targeting Akt signaling (47, 48).”
BackgroundWu, K., Li, W., Peng, G., & Li, F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908837106 · Cited by 355 · cited 6×
“Based on previous studies, Lys31 and Lys353 located on ACE2 are considered to be virus-binding hotspot residues liable for binding of S-protein (1,20).”
BackgroundMethodInfluentialPaleolithic to Bronze Age Siberians Reveal Connections with First Americans and across Eurasia
Yu, H., Spyrou, M. A., Karapetian, M., Shnaider, S., Radzevičiūtė, R., Nägele, K., Neumann, G. U., Penske, S., Zech, J., Lucas, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.037 · Cited by 216
Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229E
Bonavia, A., Zelus, B. D., Wentworth, D. E., Talbot, P. J., & Holmes, K. V. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2530-2538.2003 · Cited by 194 · cited 1×
“receptor-binding domain (RBD) and S2 subunit is responsible for the fusion of viral membrane and the host cellular membrane (17).”
BackgroundAdedeji, A. O., Severson, W., Jonsson, C., Singh, K., Weiss, S. R., & Sarafianos, S. G. (2013) · Journal of Virology · doi:10.1128/jvi.00998-13 · Cited by 183 · cited 1×
“Since this interaction is essential for SARS-CoV-2 entry into the host cell and infection, drugs targeting S-RBD–ACE2 interface protein-protein interactions could potentially inhibit the virus entry into host cell and thus, provide quick solution to control SARS-CoV-2 infections (44).”
BackgroundElshabrawy, H. A., Coughlin, M. M., Baker, S. C., & Prabhakar, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050366 · Cited by 172 · cited 1×
“present in the market, and neutralizing monoclonal antibody-based therapeutics are also being developed to combat COVID-19 (12)(13)(14)(15).”
BackgroundPlatelet Activation and Aggregation Promote Lung Inflammation and Influenza Virus Pathogenesis
Lê, V. B., Schneider, J. G., Boergeling, Y., Berri, F., Ducatez, M., Guerin, J.-L., Adrian, I., Errazuriz-Cerda, E., Frasquilho, S., Antunes, L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1031oc · Cited by 164 · cited 3×
“Eptifibatide acetate protects lungs from inflammations caused by influenza virus, and has been reported as antiviral that inhibits the protease activity of Chikungunya virus capsid protein (50, 51).”
BackgroundCoronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors
Sisk, J. M., Frieman, M. B., & Machamer, C. E. (2018) · Journal of General Virology · doi:10.1099/jgv.0.001047 · Cited by 133
Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists
Cheng, H., Lear-Rooney, C. M., Johansen, L., Varhegyi, E., Chen, Z. W., Olinger, G. G., & Rong, L. (2015) · Journal of Virology · doi:10.1128/jvi.01337-15 · Cited by 117 · cited 1×
“GR hydrochloride is an antagonist of 5-HT1B/1D serotonin receptor, and also plays a role in inhibiting entry of Ebola virus entry into host cell (45).”
BackgroundRecombinant vaccines for COVID-19
Yadav, T., Srivastava, N., Mishra, G., Dhama, K., Kumar, S., Puri, B., & Saxena, S. K. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1820808 · Cited by 105
Sabbatini, P., Korenchuk, S., Rowand, J. L., Groy, A., Liu, Q., Leperi, D., Atkins, C. L., Dumble, M. L., Yang, J., Anderson, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0423 · Cited by 105 · cited 1×
“protein Cancer drug (54) • Inhibitor of Insulin like growth factor-1 receptor (54).”
BackgroundChikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease
Singh, H., Mudgal, R. K., Narwal, M., Kaur, R., Singh, V. A., Malik, A., Chaudhary, M., & Tomar, S. (2018) · Biochimie · doi:10.1016/j.biochi.2018.04.004 · Cited by 89 · cited 1×
“Antiviral drugs blocking entry of virus or acting on replication stages have been reported against dengue, chikungunya virus and other similar RNA viruses (40,41).”
BackgroundSelf-citationSharma, R., Kesari, P., Kumar, P., & Tomar, S. (2018) · Virology · doi:10.1016/j.virol.2017.12.020 · Cited by 88 · cited 1×
“Studies suggest that targeting the capsid synthesis step could also prevent budding stage of virus (42,43).”
BackgroundSelf-citationHsu, K.-L., Tsuboi, K., Chang, J. W., Whitby, L. R., Speers, A. E., Pugh, H., & Cravatt, B. F. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400899c · Cited by 84
Inhibition of chikungunya virus by picolinate that targets viral capsid protein
Sharma, R., Fatma, B., Saha, A., Bajpai, S., Sistla, S., Dash, P. K., Parida, M., Kumar, P., & Tomar, S. (2016) · Virology · doi:10.1016/j.virol.2016.08.029 · Cited by 76 · cited 1×
“Studies suggest that targeting the capsid synthesis step could also prevent budding stage of virus (42, 43).”
BackgroundSelf-citationGNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein
Clark, M. J., Miduturu, C., Schmidt, A. G., Zhu, X., Pitts, J., Wang, J., Potisopon, S., Zhang, J., Wojciechowski, A., Chu, J. J. H., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.03.010 · Cited by 75
Tsukuda, S., Watashi, K., Iwamoto, M., Suzuki, R., Aizaki, H., Okada, M., Sugiyama, M., Kojima, S., Tanaka, Y., Mizokami, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.602540 · Cited by 73 · cited 1×
“cotransporting polypeptide (NTCP) expression (55).”
Mudgal, R. K., Mahajan, S., & Tomar, S. (2019) · FEBS Letters · doi:10.1002/1873-3468.13642 · Cited by 64 · cited 1×
“Antiviral drugs blocking entry of virus or acting on replication stages have been reported against dengue, chikungunya virus and other similar RNA viruses (40,41).”
BackgroundSelf-citationKwiatkowski, K., Piotrowska, A., Rojewska, E., Makuch, W., & Mika, J. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9729-6 · Cited by 64 · cited 2×
“The compound RS504393, identified against both ACE2 and S-RBD, targets chemokine receptor, a mechanism bywhich SARS-CoV interferes with the host immune responses (57).”
BackgroundFast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV)Preprint
Huang, Q., & Herrmann, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.01.930537 · Cited by 54
Alphavirus capsid protease inhibitors as potential antiviral agents for Chikungunya infection
Fatma, B., Kumar, R., Singh, V. A., Nehul, S., Sharma, R., Kesari, P., Kuhn, R. J., & Tomar, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104808 · Cited by 53 · cited 2×
“Eptifibatide acetate protects lungs from inflammations caused by influenza virus, and has been reported as antiviral that inhibits the protease activity of Chikungunya virus capsid protein (50, 51).”
BackgroundSelf-citationStructure of dimeric full-length human ACE2 in complex with B 0 AT1Preprint
Yan, R., Zhang, Y., Li, Y., Xia, L., & Zhou, Q. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.17.951848 · Cited by 44 · cited 1×
“In the sequence of SARS-CoV-2, the S-RBD residues directly interacting with ACE2 receptor, are similar to that of SARS-CoV, strongly signifying that ACE2 is playing a central role in SARS-CoV-2 entry into host-cell (36, 37).”
MethodKaur, R., Neetu, N. A., Mudgal, R. K., Jose, J., Kumar, P., & Tomar, S. (2018) · Virology · doi:10.1016/j.virol.2018.10.009 · Cited by 41 · cited 1×
“can thus be targeted at each of these steps of their life cycle to combat infections caused by them (39).”
BackgroundSelf-citationLi, G., Zhou, L., Zhang, C., Shi, Y., Dong, D., Bai, M., Wang, R., & Zhang, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02541 · Cited by 40 · cited 1×
“GSK is known to reduce inflammations posed by infections caused by influenza virus, whereas BMS, another inhibitor against S-RBD is proposed to inhibit Hepatitis B virus infection (48)(49) .”
BackgroundHammond, L., Krinks, C. H. V., Durham, J. N., Tomkins, S. E., Burnett, R. D., Jones, E. L., Chandraratna, R. A. S., & Brown, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1939 · Cited by 40 · cited 1×
“protein Cancer drug (59) • Inhibitor of Retinoic acid receptor.”
BackgroundBottemanne, P., Paquot, A., Ameraoui, H., Alhouayek, M., & Muccioli, G. G. (2019) · The FASEB Journal · doi:10.1096/fj.201802259r · Cited by 25 · cited 1×
“KT185 and KT203, inhibitors of S-RBD protein of SARS-CoV-2 are known to exert anti-inflammatory role on lungs (47).”
BackgroundIn silico and proteomic analysis of protein methyltransferase CheR from Bacillus subtilis
Batra, M., Sharma, R., Chandra, V., Aggarwal, M., Agarwal, U., Gupta, P. K., Singh, R. P., & Tomar, S. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.03.023 · Cited by 4 · cited 1×
“Overall, the modelled structure was good as more than 99% of the residues, after summing up, were in allowed region of Ramachandran plot (40).”
BackgroundSelf-citation
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., Burgstaller-Muehlbacher, S., De Jesus, P. D., Teriete, P., Hull, M. V., et al. (2020) · Nature · doi:10.1038/s41586-020-2577-1 · Cited by 760
A candidate multi-epitope vaccine against SARS-CoV-2
Kar, T., Narsaria, U., Basak, S., Deb, D., Castiglione, F., Mueller, D. M., & Srivastava, A. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-67749-1 · Cited by 349
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Metadata
- Authors
- Choudhary, S., Malik, Y. S., & Tomar, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-10
- Volume
- 11
- Pages
- 1664-1664
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3041591475
- Cited by
- 231
- References
- 64
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.